Background: Management of Graves disease includes antithyroid drugs, I therapy, or thyroidectomy. Our aim was to review our institutional experience with definitive treatments for Graves disease.
Methods: This was a retrospective review of patients undergoing I therapy (n = 295) or thyroidectomy (n = 103) for Graves disease (2003-2015). Demographic, clinical, pathology, and outcome data were collected from institutional databases.
Results: I therapy patients were older (39.1 years vs 33.4 years, P = .001). There was no difference in the presence of ophthalmopathy between groups. A larger proportion of children received thyroidectomy than I therapy (17.1% vs 9.2%, P = .026). The success rate of the first I therapy dose was 81.4%. Overall success rate, including additional doses, was 90.1%. Rapid turnover of iodine correlated with I therapy failure (58.3% rapid turnover failure vs 14.9% non-rapid turnover failure, P < .05). All surgical patients underwent total or near-total thyroidectomy. I therapy complications included worsening thyrotoxicosis (1%) and deteriorating orbitopathy (0.7%). Operative complications were higher than I therapy complications (P < .05) but were transient. There was no worsening orbitopathy or recurrent Graves disease among surgical patients.
Conclusion: A higher proportion of pediatric Graves disease patients underwent thyroidectomy than I therapy. Rapid turnover suggested more effective initial management with operation than I therapy. Although transient operative complications were high, I therapy complications included worsening of Graves orbitopathy among those with pre-existing orbitopathy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492886 | PMC |
http://dx.doi.org/10.1016/j.surg.2016.06.066 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!